Pyruvate Kinase Deficiency Global Longitudinal Registry
This study is like a large, ongoing look into a rare blood condition called Pyruvate Kinase Deficiency (PKD). It's not a clinical trial where you try new medicines; instead, researchers will simply gather information from people with PKD worldwide. This will help them understand how the condition naturally develops over many years, how it's treated, and how it affects daily life. Doctors will share patient information, and some details will come directly from patients or their parents. The goal is to collect a lot of useful data to eventually improve the care and understanding of PKD for everyone affected.
En un coup d'œil
De quoi parle cette étude ?
This study is looking into a rare inherited blood condition called Pyruvate Kinase Deficiency, or PKD. People with PKD have a problem with their red blood cells, which can sometimes lead to anaemia and other health issues.
Instead of testing new treatments, this study is a 'registry'. Think of it as a large, organised way to collect information from many different people with PKD around the world. The aim is to understand how PKD affects people over a long time, the types of treatments they receive, and how the condition impacts their lives. By gathering this detailed information from lots of patients, doctors can get a much clearer picture of PKD, which will hopefully lead to better ways to manage and treat it in the future.
Researchers will collect information that doctors already record, like blood test results, details about hospital visits, and different treatments given. They will also collect general details about patients, such as their age and when they were diagnosed. This information will be regularly updated over several years to see how PKD changes and how different treatments work over time.
Points clés
- This is a study to understand a rare blood condition called Pyruvate Kinase Deficiency (PKD).
- It collects information from patients worldwide, not a new treatment trial.
- Data includes existing medical records, not new tests.
- Participation is for at least 2 years, potentially up to 9 years.
- Information gathered aims to improve future care for PKD patients.
- You can stop participating at any time without affecting your care.
Qui peut être éligible ?
Anyone of any age who has been officially diagnosed with Pyruvate Kinase Deficiency (PKD) can potentially join this study. This diagnosis usually needs to be confirmed by a genetic test, which looks at your genes.
Even if your genetic test results are unusual or new, you might still be able to join if your doctor believes your genetic changes are definitely causing your PKD.
Importantly, you or your parent/guardian (if you are a child) must be willing and able to give your clear permission to take part.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Do you have a confirmed diagnosis of Pyruvate Kinase Deficiency (PKD)?
- Was your PKD diagnosis confirmed by a genetic test?
- Are you (or your parent/guardian) willing to give permission for your medical information to be shared for this study?
- Are you of any age?
En quoi consiste la participation ?
If you decide to take part, doctors will regularly share information they already collect about your condition with the study. This includes details from your medical records, like blood test results (such as haemoglobin levels, which tell us about your red blood cells), and any treatments you're receiving (like blood transfusions or medicines). You won't have any extra appointments or tests specifically for this study. Your doctors will just provide updates on your health status once a year based on your usual check-ups. The study plans to collect information for at least two years and potentially up to nine years, but you can choose to leave the study at any time.
Risques et avantages potentiels
Locations (52)
- Hôpital pour enfants de PhoenixCode postal vérifiéPhoenix, États-Unis
- Hôpital pour enfants de l'ArkansasCode postal vérifiéLittle Rock, États-Unis
- University of Arkansas for Medical SciencesCode postal vérifiéLittle Rock, États-Unis
- Children's Hospital of Orange CountyCode postal vérifiéOrange, United States
- Stanford University Medical CenterCode postal vérifiéPalo Alto, United States
- Children's Healthcare of AtlantaCode postal vérifiéAtlanta, États-Unis
- Hôpital Général du MassachusettsCode postal vérifiéBoston, États-Unis
- Boston Children's HospitalCode postal vérifiéBoston, États-Unis
- UMass Memorial Medical CenterCode postal vérifiéWorcester, United States
- Children's Hospital of MichiganCode postal vérifiéDetroit, United States
- Centre Médical de l'Université DukeCode postal vérifiéDurham, États-Unis
- Children's Hospital of PhiladelphiaCode postal vérifiéPhiladelphie, États-Unis
Questions fréquentes
What is Pyruvate Kinase Deficiency (PKD)?
PKD is a rare inherited blood condition where red blood cells don't work properly, which can lead to anaemia and other health issues.
Is this a study where I try a new medicine?
No, this is not a study where you try new medicines. It's an information-gathering study to learn more about PKD.
Will I have extra doctor's appointments?
No, you won't need extra appointments. Information will be collected from your regular doctor's visits.
Combien de temps durera l'étude ?
The study aims to collect information for at least 2 years, and possibly up to 9 years in total.
Puis-je arrêter de participer si je change d'avis ?
Yes, you can choose to stop participating at any time without it affecting your medical care.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.